The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a safety advisory regarding the use of GLP-1 receptor agonist medicines — a class of drugs commonly used for weight loss and type 2 diabetes treatment. The agency emphasizes that these medications should not be used during pregnancy, while attempting to conceive, or while breastfeeding.
These medications, which include popular brand names such as Ozempic, Wegovy, Mounjaro, Saxenda, and Victoza, mimic the hormone GLP-1 to regulate blood sugar and appetite. However, the MHRA stresses that there is currently insufficient safety data about their potential effects on a developing fetus.
Key Health Warning for Women of Reproductive Age
According to the MHRA, women who are planning to become pregnant should discontinue GLP-1 drugs at least two months before trying to conceive. In addition, women currently using these medications are strongly advised to use effective contraception throughout treatment.
One of the drugs, Mounjaro (tirzepatide), has been found to interfere with oral contraceptives, particularly among individuals who are overweight. The MHRA recommends the use of barrier methods like condoms, especially during the first four weeks of treatment or after any dose adjustments.
Unexpected Pregnancies Raise Concerns
There have been 40 pregnancy-related reports submitted to the MHRA involving women on these medications. While it is unclear whether all pregnancies were unintentional, some women reported surprise pregnancies, even while using contraception. Online discussions have dubbed these occurrences “Ozempic babies” or “Mounjaro babies.”
Out of these reports:
- 26 were linked to Mounjaro,
- 8 involved Ozempic or Wegovy,
- 9 related to Victoza or Saxenda.
Dr. Alison Cave, Chief Safety Officer at MHRA, issued a strong reminder that these medications are prescription-only and are not designed for cosmetic or aesthetic weight loss.
“They are not a quick fix to lose weight and have not been assessed to be safe when used in this way,” said Dr. Cave. She also urged patients to consult healthcare professionals and thoroughly read medication leaflets before starting treatment.
Bridget Phillipson, Minister for Women and Equalities, reinforced the need for women to be fully informed. “This is a new and evolving area,” she said, “and it’s vital to stay updated on both the benefits and risks.”
